MedTrace Logo

A Global Imatinib and Nilotinib Pregnancy Exposure Registry

NCT01289054 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4

Last updated 2015-04-15

No results posted yet for this study

Summary

This is a voluntary, international, primarily prospective, observational, exposure-registry and follow-up study of women receiving Imatinib and Nilotinib during pregnancy or within six months prior to pregnancy.

Conditions

  • All Indications for Glivec/Gleevec and Tasigna

Interventions

DRUG

Tasigna

DRUG

Gleevec

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01289054 on ClinicalTrials.gov